Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KleanLyte is an osmotic laxative used for cleansing the colon in preparation for colonoscopy. It is an oral sulfate solution (OSS) consisting of a combination of sodium sulfate, potassium sulfate, and magnesium sulfate. Marketed in Canada by Pendopharm (a division of Pharmascience), KleanLyte works by creating an osmotic gradient that draws water into the bowel, thereby increasing stool volume and stimulating peristalsis to clear the colon. It is typically administered as a split-dose regimen. Clinical studies, such as those conducted by the University of Manitoba, have evaluated its efficacy and tolerability specifically in patients with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, comparing it to standard polyethylene glycol (PEG) solutions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KleanLyte.